MB
TRDA icon

MPM BioImpact’s Entrada Therapeutics TRDA Stock Holding History

MPM BioImpact’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.22M Buy
+1,253,053
New +$12M 0.56% 34

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MPM BioImpact's TRDA Position: Q2 2026 in Review

MPM BioImpact opened a new position in Entrada Therapeutics (TRDA) in Q2 2026: 1,253,053 shares worth $9.22M. The stake represents 0.56% of the portfolio and ranks #34 among its holdings.

116 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • MPM BioImpact held 1,253,053 shares of Entrada Therapeutics worth $9.22M as of Q2 2026.
  • Entrada Therapeutics was a new MPM BioImpact position in Q2 2026.
  • Entrada Therapeutics made up 0.56% of MPM BioImpact's portfolio in Q2 2026, its #34 holding.
  • 116 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.